This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. This includes an upfront payment of $2m from AstraZeneca.
Jude Children’s Research Hospital scientists have developed a highly efficient method to address a major challenge in biology–identifying the genetic ‘switches’ that regulategeneexpression. Credit: St. Jude Children’s Research Hospital St.
The investigational adeno-associated virus (AAV) gene therapy candidate NGN-401 is claimed to be the first to deliver the full-length human MECP2 gene using the company’s Expression Attenuation via Construct Tuning (EXACT) generegulation technology.
The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (or miRNA) and its role in post-transcriptional generegulation. This control plays a critical role in development and cellular function.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: The plant hormone auxin may promote disease by regulating virulence gene expression.Scientists have long known that the plant hormone auxin controls many aspects of plant growth, development, … Continue reading →
Related: Obesity-Focused Metsera Launches IPO Amid Much Anticipation Aardvarks approach centers on developing novel, small-molecule drugs that harness the bodys natural hunger-regulating mechanisms. Alongside ARD-101, Aardvark is developing ARD-201, a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 inhibitor.
The aberrant protein complex is essential for regulating leukaemia-promoting geneexpression. A resistant mutation, MEN1-M3271, developed in one of 29 patients, detected at the end of Cycle 4, but the patient maintained stable disease through Cycle 7. The median age of RP2D patients in the study was 70.5
Innovation S-curve for the pharmaceutical industry Transcription factors for genetically modified cells is a key innovation area in the pharmaceutical industry Transcription factors are proteins which control geneexpression by controlling the rate of transcription of genetic information from DNA to RNA.
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that geneexpression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. Global Development Leader, Immunology at Lilly. ” About The Studies.
California-based Sangamo Therapeutics is one such company that believes in the powerful potential of in vivo genome editing and regulation, together known as genome engineering, and has built up a sizable preclinical pipeline of genome regulation treatments for diseases such as Huntington’s disease and Amyotrophic lateral sclerosis (ALS).
Another therapy by the same company named GTX-102 is also an antisense therapy; however, it silences geneexpression by binding to the RNA molecule that regulates its expression. It is designed to target and inhibit the molecule that silences the paternal copy of the gene, called UBE3A antisense transcript (UBE3A-AS).
Scientists discover small RNA that regulates bacterial infection People with weakened immune systems are at constant risk of infection. Abell Chair in Molecular and Cellular Biology – and Pengbo Cao, a postdoctoral researcher in Whiteley’s lab, discovered a gene that drives the switch. aeruginosa infections.
Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. It’s a great tool for controlling geneexpression.”.
AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. It’s not the big pharma’s first foray into the transcription factor area.
bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was “very unlikely” to be caused by the gene therapy. bluebird bio’s Philip Gregory.
Type of GeneRegulation Based on the type of transcription factor ( activators / repressors ), generegulation has been categorized into positive and negative generegulation. When activator binds to the operon, it either speeds up or permits geneexpression.
Biomarker testing is being pursued to identify biological signs of the disease and provide an approach to develop personalized treatment plans for each patient. As this technology continues to evolve, it is expected to help identify glaucoma in its nascent stages of development.
The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for new drug targets.
The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. The delivery vector – an AAV8 capsid – is designed to allow geneexpression directly in target tissues like skeletal muscle.
The company focuses on so-called ‘undruggable’ targets – those that have defied the efforts of drug developers using conventional treatment approaches.
InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulategeneexpression in cells.
Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. These modifications regulategeneexpression without altering the sequence or structure of DNA.
The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds. Angelman syndrome is a result of the missing or dysfunctional gene known as UBE3A. GeneTx and Ultragenyx are co-developing the therapy.
It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson’s could have their causes here – not to mention depressions and autistic disorders.
The approach will allow researchers to understand the role individual genes play in normal cell growth and development, in aging, and in such diseases as cancer, said Shiri Levy, a postdoctoral fellow in UW Institute for Stem Cell and Regenerative Medicine (ISCRM) and the lead author of the paper. it can be reawakened.
This process is often described as a ‘seed’ (circulating tumor cell) that must fall on fertile ‘soil’ (metastatic niche) for a new tumor to develop at the distant site. In this way, the scientists were able to observe the development of metastases in the absence of the primary tumor.
Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence geneexpression, respectively. It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering.
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Like all drugs, biologics are regulated by the FDA.
Manual manipulation affects geneexpression,” he pointed out, so minimizing that, as well as the vast quantities of plastics typically required, results in a more controlled process and a more consistent product. One of the challenges is balancing the clinical and manufacturing aspects of development. “If
The identification of T cells that essentially ‘hide’ the virus has significant implications for developing therapeutic strategies to improve the treatment and long-term management of HIV. This may help explain why HIV is adequately controlled, but not eradicated, with current treatments. The research study was published in Cell Reports.
executive vice president of Research and Development at Amgen. AstraZeneca continues to lead development and Amgen continues to lead manufacturing. Reese , M.D., ” Amgen and AstraZeneca Collaboration
Earlier in 2020, Amgen and AstraZeneca updated the 2012 collaboration agreement for tezepelumab.
BOSTON – An important player in the healthy development of female embryos turns out also to play a key role in regulating the behavior of chromosome loops and geneexpression in both sexes, according to a new study by researchers at Massachusetts General Hospital (MGH).
Focusing on biologics, vaccine development and policy platforms in anticipation of an eventual outbreak is why we’re where we are today in terms of the positive side [of the pandemic].”. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Pandemic Efforts. Diagnostics.
Fructose as a key player in the development of fatty liver disease. The trans-fat ban–food regulation and long-term health. How does brain insulin resistance develop in Alzheimer’s disease? Effect of Glucocorticoid-Induced Insulin Resistance on Follicle Development and Ovulation. The Journal of Nutrition. DOI: 10.3945/jn.108.098020.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content